Get an email when this journal's indexing changes
Added to or removed from Scopus, Web of Science, ABDC, DOAJ, FT50, UT Dallas or ONOS. One confirmation click; unsubscribe anytime.
Blood Cancer Discovery is Scopus-indexed (Q1, CiteScore 13.9), WoS ESCI. Published by American Association for Cancer Research Inc..
Checked against the index lists dated .
ISSN 2643-3230Verify ISSN ↗2643-3249Verify ISSN ↗
Publisher: American Association for Cancer Research Inc.
Cost to publish: No APC data — check the publisher
| Subject area | Rank | Pctile | Q |
|---|---|---|---|
| Biochemistry, Genetics and Molecular Biology (miscellaneous) | 5 / 144 | 96th | Q1 |
| Hematology | 11 / 151 | 93rd | Q1 |
| Oncology | 35 / 428 | 91st | Q1 |
| Cancer Research | 28 / 233 | 88th | Q1 |
Not listed in: DOAJ, ABDC, ABS / AJG, FT50, UT Dallas, ONOS (subscription), ONOS (APC covered)
Yes — actively indexed in Scopus, coverage 2020–present, best quartile Q1, CiteScore 13.9.
Blood Cancer Discovery is Q1 in Biochemistry, Genetics and Molecular Biology (miscellaneous) (rank 5 of 144), Q1 in Hematology (rank 11 of 151) and Q1 in Oncology (rank 35 of 428), by CiteScore 2025. It is ranked in 4 subject areas in all.
Blood Cancer Discovery is indexed in the Emerging Sources Citation Index, so it may have a Journal Impact Factor in Clarivate's Journal Citation Reports. JCR is paid, so check it for the current value. The closest free measure is its Scopus CiteScore 13.9, which places it in quartile Q1 at the 96th percentile of its subject. Its SCImago Journal Rank (SJR, a free Scopus-based metric) is 4.623, quartile Q1, with an H-index of 35.
Blood Cancer Discovery is published by American Association for Cancer Research Inc. Its print ISSN is 2643-3230 and its online ISSN is 2643-3249.
Yes — indexed in the Emerging Sources Citation Index.
No — it is not registered as an open-access journal in DOAJ or Scopus.
Blood Cancer Discovery has an h-index of 46 and a 2-year mean of 2.77 citations per paper (OpenAlex). Its Scopus CiteScore is 13.9, quartile Q1. On 2-year citations it ranks #50 of 141 Scopus journals in Biochemistry, Genetics and Molecular Biology (miscellaneous).
Blood Cancer Discovery published 71 papers in 2025; its busiest recent year was 2020 with 135. 2026* is the year so far.
h-index, i10-index and 2-year mean citedness are open, licence-clear metrics from OpenAlex — not a proprietary impact factor. The subject rank counts only journals that OpenAlex has a figure for; it is not a Scopus or Clarivate ranking. Updated 2026-10-14.
In its latest 92 research articles (2025–2026), authors are most often from United States (53.3%), Germany (9.9%) and Canada (7.6%). More than half of recent authorship comes from one country.
Countries are counted fractionally, so a paper by authors from two countries counts half to each.
Scopus status: Active. 2 retracted papers are recorded (2.8 per 1,000 papers). The Problematic Paper Screener flags none of its papers. These are indicators to check, not findings against the journal.
Retractions from OpenAlex; flags from the Problematic Paper Screener (Cabanac, Labbé & Magazinov, CC BY), 2026-09-21 export. A flag marks a paper for a closer look; it is not a finding against the journal.
Index data is curated from public sources (Scopus, Web of Science, ABDC, FT50, UT Dallas, DOAJ). CiteScore and quartiles reflect the latest available Scopus release. Always verify a journal's current status on its official source before submitting.
Comments load as you scroll here.